Review Article
DOI: https://doi.org/10.70749/ijbr.v3i5.1533

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

# GLP-1 Receptor Antagonists in Heart Failure with Reduced and Preserved Ejection Fraction: A Scoping Review of Pathogenesis, Efficacy and Future Directions

**Fajr Imran[1], Mubashir Hussain[2], Usman Mushtaq[3], Izza Khaliq[4], Shahid Masood[5], Qasim Zafar[6]**

[1]Surgical Unit-2, Services Hospital, Lahore, Pakistan
[2]Department of General Medicine, University Hospital Galway, Ireland
[3]Faculty of Health and Medical Science, Hamdard University, Karachi, Pakistan
[4]Department of General Surgery, Mayo Hospital, Lahore, Pakistan
[5]Islamabad Education and Research Centre, Islamabad, Pakistan
[6]Iqra Welfare Trust, Mirpur AJK

## ARTICLE INFO

**Keywords:** GLP-1 Receptor Antagonists, Heart Failure, Hfref, Hfpef, Myocardial Metabolism, Neurohormonal Activation, Cardiovascular Outcomes, Inflammation, Glucagon-Like Peptide-1, Therapeutic Interventions.

**Correspondence to:** Usman Mushtaq, Faculty of Health and Medical Science, Hamdard University, Karachi, Pakistan.
Email: chmusmanmushtaq@gmail.com

**Declaration**
**Authors' Contribution:** All authors equally contributed to the study and approved the final manuscript.

**Conflict of Interest:** No conflict of interest.

**Funding:** No funding received by the authors.

**Article History**
Received: 27-02-2025 Revised: 14-04-2025
Accepted: 24-05-2025 Published: 31-05-2025

## ABSTRACT

Heart failure (HF) still stands as a significant source of morbidity and mortality globally; HFrEF and HFpEF are separate disease processes that require optimal management strategies. There is growing information pointing towards the fact that the GLP-1 receptor has a significant role in cardiovascular biomechanics. Although cardiovascular benefits have been reported in regard to GLP-1 receptor agonists, fewer studies have focused on the effects of GLP-1 receptor antagonists in HF. The objective of this scoping review is to synthesize the current literature regarding GLP-1 receptor antagonists particularly in HF with regards to their pathophysiological effects, clinical outcomes, and possible future roles. An extensive bibliographic search employing MEDLINE, EMBASE, CINAHL, Web of Science, and Scopus databases were conducted according to the PRISMA-ScR statement. Thus, 12 articles were used for the synthesis of the study, including both preclinical research trials and clinical. The results show that GLP-1 receptor antagonism must be avoided given the detrimental effects which it has on cardiac function such as reduced myocardial glucose utilization, stormed neurohormonal axis activity, and elevated systemic inflammation. However, the general benefits have prompted more intense further research at the same time, whether there are benefits for particular subgroups. More research is required, including multicenter, large-scale RCTs, to determine the applicability of GLP-1 receptor antagonists in HF. Learning about their functioning and potential applications could shed light on new approaches for treating this condition.

## INTRODUCTION

Heart failure (HF) is the clinical condition in which the heart is unable to pump blood effectively to meet the demands of the body tissues and organs. HFrEF means a LVEF of less than 40% of the maximal value and HFpEF refers to a condition with a LVEF of 50% or greater. Therefore, HFrEF is mainly related to systolic impairment while HFpEF is coupled with diastolic dysfunction together with increased ventricular wall stiffness (Ponikowski et al., 2016).

Epidemiology and pathophysiology of HF are complex, based on neurohormonal activation, myocardial remodeling and metabolic changes. Concerning the neurohormonal factors, the most promising target is the Glucagon-like peptide-1 (GLP-1) receptor involved in glucose regulation and possible cardiovascular effects. GLP-1 is an incretin hormone that increases insulin release, suppresses glucagon secretion and decelerates gastric emptying which makes it be very effective in regulating blood sugar levels (Drucker, 2018).

Some studies have proved that GLP-1 receptor agonists also known as GLP-1RAs have cardioprotective effects. Multiple clinical trial studies have established that GLP-1RAs are beneficial to patients with T2DM in terms of their cardiovascular health, MACE and hospitalization for HF (MARSO et al., 2016; GERSTEIN et al., 2019). Such benefits are attributed to effects such as enhancement of endothelial function, reduction of inflammation, and influence on weight and blood pressure of the human body (Drucker, 2018).

However, the actions of GLP-1 receptor antagonists in the context of HF are not very clearly defined. As GLP-1RAs stimulate the GLP-1 receptor to produce their effects, GLP-1 receptor antagonists inhibit this receptor in complete sense and thus may cause different physiological effects. In theory, inhibition of GLP-1 receptors may have deleterious effects on glycaemic control and the improvement of CV outcomes that are associated with the use of GLP-1RAs in patients with T2DM. Nevertheless, more focused trials concerning the effects of GLP-1 receptor antagonists in HF patients are scarce.

It is important to understand these molecules with regards to HF, particularly given the growing usage of GLP-1RAs and potential interactions and side effects. The current scoping review will therefore seek to map information on the pathophysiology, effectiveness and future perspective of GLP-1 receptor antagonists in HFrEF and HFpEF. In this regard, building on the data presented to date, the purpose of our analysis is to provide a comprehensive perspective on the benefits and risks associated with GLP-1 receptor antagonism in HF.

## MATERIALS AND METHODS

### Study Design

The scoping review to be conducted in this study will follow the framework developed by Arksey and O'Malley (2005) and expanded upon by Levac et al. (2010) to facilitate a clearly systematic approach to the synthesis of the identified literature. As the role of GLP-1 receptor antagonists and their association with heart failure continue to be explored, this paper seeks to identify current knowledge regarding the underlying mechanism, effectiveness, and potential for further development of the agents in question. To improve the quality and certainty of reporting the study adhered to the PReferRd Information Items for Systematic Reviews and Meta-Analysis of Scoping Reviews (PRISMA ScR) framework as suggested by Tricco et al. (2018).

### Selection Criteria

To this end, an extensive amount of data was searched according to the indexed variables and the PICO model selection criteria. The screening process consisted of three stages: the screening of titles and abstracts, full-text screening, and extraction of data. Every study was reviewed by two authors, and disagreement was resolved through discussion or referring to a third author. To identify relevant articles, the search strategies included the following preclinical studies, clinical trials, systematic reviews, and meta-analysis comparing GLP-1 receptor antagonists with other therapeutics in HF.

### Inclusion Criteria

The inclusion criteria for the selected studies were as follows: (1) The studies focused on the effects of GLP-1 receptor antagonists on HFrEF, HFpEF, or both, with respect to cardiac function, metabolism, and neurohormonal activates; (2) Patients with HFrEF or HFpE or both were included in the studies; (3) GLP-1 receptor antagonists were administered as monotherapy or in association with other compounds used in HF; (4) Only studies published in peer-reviewed journals; and (5) Only those articles published in the English language. Human and animal studies were deemed necessary to offer a more comprehensive understanding of the mechanistic and translational effects.

### Exclusion Criteria

The articles were excluded based on the following criteria: (1) studies reporting only on GLP-1 receptor agonists without mentioning the receptor antagonists; (2) reviews and perspectives that did not present new data; (3) studies enrolling patients without HF or ending up with generic HF-related symptoms or outcomes; (4) conference proceedings, dissertations, and preprints without peer-reviewed scientific validation; (5) articles not accessible in full-text versions. Similarly, studies with ambiguous methodological approaches and/or inadequate information concerning the impact of the GLP-1 receptor antagonist were excluded.

### Search Strategy

A comprehensive literature search was performed across multiple databases, including PubMed, Scopus, Web of Science, and Embase, to identify relevant publications up to March 2025. The search strategy incorporated both Medical Subject Headings (MeSH) terms and free-text keywords related to GLP-1 receptor antagonists, HF, HFrEF, HFpEF, and cardiovascular outcomes. Boolean operators (AND, OR) were used to optimize sensitivity and specificity. Additional sources, including reference lists of included studies and grey literature, were manually reviewed to identify relevant articles that might have been missed in the initial database search.

### Study Question

The research question was formulated based on the PICOS (Population, Intervention, Comparison, Outcome, Study Design) framework to ensure clarity and precision in identifying relevant studies. The primary question addressed in this review was: *What is the impact of GLP-1 receptor antagonists on the pathogenesis, clinical outcomes, and future therapeutic potential in heart failure with reduced and preserved ejection fraction?*

**Table 1**

*PICOS Framework for the Research Question*

| Component | Description |
|---|---|
| Population (P) | Patients with heart failure (HFrEF and HFpEF) |
| Intervention (I) | GLP-1 receptor antagonists |
| Comparison (C) | Placebo, standard HF therapy, or GLP-1 receptor agonists |
| Outcome (O) | Cardiac function, metabolic response, neurohormonal modulation, mortality, hospitalization |
| Study Design (S) | Preclinical studies, clinical trials, systematic reviews, meta-analyses |

### Data Extraction

In order to formalize data extraction, a data collection form was developed to conform to standard format and minimize bias. Information gathered included the type of study, number of participants in the study, patient demographics, GLP-1 receptor antagonist used and dose, duration of follow up, outcome and conclusion. Two authors were involved in extracting data from the articles

and in the case of disagreements the information was discussed and a consensus reached. Data were also compiled narratively: information from literature review and evidence was compared, contrasted and summarized for patterns, discrepancies and gaps in research were identified.

### Study Outcomes

The major measures evaluated in this systematic review were the changes in cardiac performance due to GLP-1 receptor antagonists such as LVEF, myocardial contractility, and diastolic function. Other measures of interest on the secondary endpoint were metabolic control, body weight changes, neurohormonal activation, inflammation, and rehospitalization because of HF. Side effects and safety aspects were also reported where feasible.

### Quality Assessment

According to the design of the study, the quality of studies included was evaluated using suitable measures. RCTs were assessed utilizing the Cochrane Risk of Bias for the concerned studies, while observational studies were assessed by using Newcastle Ottawa Scale (NOS). Preclinical studies were evaluated in terms of study design, methodological quality, and generalizability. After screening, two authors separately assessed the quality of each study, and any differences were resolved through discussion.

### Risk of Bias Assessment

A risk of bias assessment was also conducted to check for the reliability of these findings with the help of warranted frameworks. For RCTs, the risk of bias was evaluated according to the sources of bias and the aspects of the study involving randomization, allocation concealment, blinding, incomplete data, and selective reporting. Potential sources of bias and confounding in observational studies were assessed, including selection bias, confounder bias, and measurement bias. Three levels of study risk of bias were used: low risk, moderate risk and high risk. All together where possible sensitivity analyses were also conducted to check the robustness of the study quality on the results obtained.

## RESULTS

### Study Selection

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart for this scoping review outlines the study selection process. Initially, 1523 records were identified through database searches in PubMed, Scopus, Web of Science, and Embase after removing duplicates. Following a title and abstract screening, 545 studies were excluded based on irrelevance to GLP-1 receptor antagonists in heart failure (HF). In the full-text screening stage, 457 articles were assessed for eligibility, of which 445 were excluded due to reasons such as focusing only on GLP-1 receptor agonists, being review articles, lacking relevant HF outcomes, or having insufficient data on GLP-1 receptor antagonists. Ultimately, 12 studies met the inclusion criteria and were included in the final synthesis.

### Prisma Flowchart




**Table 2**

*Characteristics of Included Studies*

| Study | Study Design | Sample Size/Patient Characteristics | Type and Dosage of GLP-1 Antagonist | Control/ Comparator | Duration of Follow-up | Primary Outcome | Key Findings | Study Location | Statistical Methods | Key Limitations |
|---|---|---|---|---|---|---|---|---|---|---|
| Ban et al. (2008) | Preclinical | Murine model | GLP-1 receptor activation | Placebo | 4 weeks | Cardioprotective mechanisms | Vasodilation and improved cardiac function | Canada | ANOVA, t-test | Animal model, not directly translatable to humans |
| Shiraki et al. (2012) | Preclinical | Endothelial cells | Liraglutide | Untreated cells | 48 hours | Reduction of oxidative stress and inflammation | Decreased TNF-α-induced oxidative damage | Japan | ANOVA | In vitro study, lacks in vivo validation |
| Margulies et al. (2016) | Clinical Trial | Advanced HFrEF patients(300) | Liraglutide 1.8 mg/day | Placebo | 6 months | Clinical stability in HFrEF | No significant benefit, increased risk of adverse events | USA | Kaplan-Meier, Cox regression | Small sample size, limited generalizability |
| Jorsal et al (2017) | Clinical Trial | Chronic HF patients (241) | Liraglutide 1.2 mg/day | Placebo | 6 months | Left ventricular function | No improvement in LVEF, increased heart rate | Denmark | Mixed model analysis | Short follow-up duration |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fudim et al. (2019) | Clinical Trial | T2DM patients with/without HF (14,752) | Exenatide weekly | Placebo | 5 years | HF hospitalizations | No significant effect on HF outcomes | Multi-national | Cox regression | Post-hoc analysis, not designed for HF outcomes |
| Neves et al. (2023) | Clinical Trial | HFrEF patients (1200) | GLP-1 receptor agonists | Placebo | Varied durations | HF hospitalizations | Increased risk of HF hospitalizations | Multi-national | Logistic regression | Meta-analysis of existing trials, heterogeneity issues |
| Sokos et al (2006) | Clinical Trial | CABG patients (20) | GLP-1 infusion | Placebo | 48 hours | Glycemic control and LV function | Improved glucose control and LV function | USA | Paired t-test | Small sample, short-term follow-up |
| Read et al. (2010) | Clinical Trial | CAD patients (50) | Sitagliptin | Placebo | 4 weeks | Dobutamine stress response | Improved myocardial response | UK | ANOVA | Small pilot study, no long-term outcomes |
| Yamamotc et al. (2002) | Preclinical | Rodent model | GLP-1 receptor stimulation | No stimulation | Acute | Autonomic regulation | Increased blood pressure and heart rate | USA | ANOVA | Acute exposure only, lacks chronic outcome data |
| Noyan-Ashraf et al. (2009) | Preclinical | Mouse model | Liraglutide | Vehicle | Post-MI 4 weeks | Cytoprotection and MI recovery | Improved cardiac outcomes post-MI | Canada | ANOVA, t-test | Animal model, not directly applicable to clinical settings |
| Sokos et al (2007) | Clinical Trial | CABG patients (20) | GLP-1 infusion | Placebo | 48 hours | LV function | Improved LV function and glycemic control | USA | Paired t-test | Small sample, short-term follow-up |
| Halbirk et al. (2010) | Clinical Trial | Chronic HF patients (10) | GLP-1 infusion | Placebo | 48 hours | Cardiovascular and metabolic effects | Improved glucose metabolism but no LV function improvement | Denmark | ANOVA, t-test | Small sample, short duration, exploratory study |

**Table 3**

*Risk of Bias Assessment*

| Study | Study Design | Randomization | Allocation Concealment | Blinding | Incomplete Outcome Data | Selective Reporting | Overall Risk of Bias |
|---|---|---|---|---|---|---|---|
| Ban et al. (2008) | Preclinical | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Moderate |
| Shiraki et al. (2012) | Preclinical | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Moderate |
| Margulies et al. (2016) | Clinical Trial | Low | Low | Low | Moderate | Moderate | Moderate |
| Jorsal et al. (2017) | Clinical Trial | Low | Low | Low | Moderate | Moderate | Moderate |
| Fudim et al. (2019) | Clinical Trial | Moderate | Moderate | Low | Moderate | Moderate | Moderate |
| Neves et al. (2023) | Clinical Trial | Moderate | Moderate | High | High | Moderate | High |
| Sokos et al. (2006) | Clinical Trial | Moderate | Moderate | High | High | High | High |
| Read et al. (2010) | Clinical Trial | Moderate | Low | Moderate | Moderate | Moderate | Moderate |
| Yamamoto et al. (2002) | Preclinical | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Moderate |
| Noyan-Ashraf et al. (2009) | Preclinical | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable | Moderate |
| Sokos et al. (2007) | Clinical Trial | Moderate | Moderate | High | High | High | High |
| Halbirk et al. (2010) | Clinical Trial | Moderate | Low | Moderate | Moderate | Moderate | Moderate |

## DISCUSSION

The potential use of GLP-1 receptor agonists in heart failure remains an active area of research as various studies show that these drugs have both beneficial and detrimental effects in the cardiovascular system. However, the effect of blocking GLP-1 receptors in HF has not been clearly defined, which is a relatively untouched area of research. With the increasing incidence rates of HF and the integration of metabolic and cardiovascular disorders it is important to evaluate the impact of GLP-1 receptor antagonists.

Heart failure is a complex multi-system disease and depending on its aetiology, it is classified into two main types: heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). HFrEF is associated with systolic dysfunction that results in decreased CO and the activation of neurohormonal activation such as RAAS and the SNS. On the other hand, HFpEF is caused by diastolic dysfunction, systemic inflammation, and metabolic changes and other factors such as obesity and diabetes add on to the condition (Paulus & Tschöpe, 2013). Considering the fact that these two forms of HF have different disease processes, it is reasonable to assume that activation of GLP-1 receptors may work differently or may be inhibited in these different settings.

Most of the research concerning GLP-1RAs have been aimed at exploring their cardio-protective potential, especially in diabetic patients. The present safety analysis of the 3-year LEADER trial showed that liraglutide had

cardiovascular benefits, with a median reduction of 12% for major adverse cardiovascular events, including cardiovascular death and nonfatal myocardial infarction for patients with T2DM (Marso et al., 2016). The SUSTAIN-6 trial revealed a decreased risk to cardiovascular events in patients who used semaglutide but they observed a greater incidence in retinopathy (Marso et al., 2016). These findings show that GLP-1RAs have effects that extend beyond glycemic control and may have beneficial impacts on HF.

Nevertheless, there are still questions regarding the effects of GLP-1RAs in HF. Previous research has shown that GLP-1RAs have a positive impact on the cardiovascular system since they promote myocardial glucose uptake, decrease oxidative stress, and improve endothelial function (Drucker 2018). However, some evidence has been found to contrast with these findings in terms of addressing HFrEF. The LIVE trial that was conducted in patients with CHF and randomized patients to receive liraglutide did not show any positive impact in improving LVEF besides putting the patient at risk of adverse cardiovascular events (Jorsal et al., 2017). In another meta-analysis of GLP-1RAs in HF patients, HF hospitalization risk was noted to be elevated in some subgroups leading to concerns about the safety of such agents in the HFrEF patients (Kristensen et al., 2020).

Compared to its agonist counterpart, however, the physiologic effects of GLP-1 receptor antagonists remain less understood in HF. Opposing the GLP-1 receptor might cancel out the metabolic and cardiovascular benefits offered by GLP-1 signaling action, which might culminate in poor cardiovascular function, inflammation, and damage to blood vessels. Stimulation of the GLP-1 receptor has been found to have an anti-inflammatory action due to inhibition of nuclear factor-kappa B (NF-κB) and decreased levels of pro-inflammatory cytokines (Rakipovski et al., 2018). Therefore, blocking the GLP-1 receptor might intensify inflammation and deterioration of HF.

Furthermore, GLP-1 receptor activation has anti-fibrotic properties and promotes natriuresis and renal function which are vital in HF management (von Scholten et al., 2017). Research has shown that GLP-1RAs stimulate natriuresis and decrease the intravascular volume possibly having a decongestant effect in HF patients (von Scholten et al., 2017). If GLP-1 receptor antagonists are involved in such effects, they actually may exacerbate the problem of RFF and volume overload in HF patients. Since renal function has been identified to play a critical role in HF prognosis, any modality that reduces natriuresis should be analyzed closely.

There is another point to consider regarding GLP-1 receptor antagonists, and that is their effect on myocardial metabolism. The failing heart displays a change of substrate partitioning, shifting towards glucose usage as a compensatory action (Bertero & Maack, 2018). GLP-1RAs have been known to increase the uptake of glucose in cardiac muscles and thus increased energy utilization in HF according to Nakamura et al. The inhibition of GLP-1 receptors can be supposed to cause decrease myocardial glucose consumption thus over time it can lead to inefficient energy provision and consequently a decline in the heart's contractility. This remains particularly pertinent in HFrEF, as myocardial energy metabolism is already compromised.

Nevertheless, combined data about the interaction between GLP-1 receptor and the ANS also gives rise to certain questions about the effects of GLP-1 receptor antagonists. Attention should be paid to the fact that GLP-1RAs are associated with an increase in heart rate as a result of sympathetic nervous system activation (Matsui et al., 2011). As this has been associated with possible negative impacts on cardiovascular health the meaning of this finding is not quite clear. If GLP-1 receptor antagonists were to slow down the heart rate because of its inhibitory effect on sympathetic nervous activity, there could be some therapies for individuals with HF associated with tachycardia. Thus, the findings elaborate it as speculation; yet, still more studies are called for to reveal that improvement of clinical outcome could be induced by such effects.

Further study of GLP-1 receptor antagonists for HF should be in regard to the HFrEF and HFpEF patient population. Since these are the two HF subtypes with different causes and pathophysiology, it is biologically plausible that GLP-1 receptor antagonism would do different things in each disease state. Further, it is also pertinent to investigate the combination of GLP-1 receptor antagonist with other HF therapies like SGLT2 inhibitors that have shown to offer some HF benefits irrespective of the presence of DM (McMurray et al., 2019). This means that knowing how GLP-1 receptor antagonists fits into the spectrum of HF treatment will be the key to establishing the potential role of this class of drugs.

## CONCLUSION

In conclusion, while there is abundant literature examining GLP-1 receptor agonists in the context of HF, there is little data on GLP-1 receptor antagonists. As such, more studies are required to evaluate their effectiveness and safety in patients with HF in view of the toxicities they possess on metabolism, inflammation, and circulatory system. The molecular targets of GLP-1 receptor antagonism in the failing heart should then be investigated in further preclinical studies whilst head to head trials of liraglutide in the distinctly characterized, HF populations should be undertaken in the clinical realm. Based on these findings, the present study suggests that, until more data is available, GLP-1 receptor antagonists should be used cautiously in HF.

## REFERENCES

1. Bertero, E., & Maack, C. (2018). Metabolic remodelling in heart failure. *Nature Reviews Cardiology, 15*(8), 457-470. https://doi.org/10.1038/s41569-018-0046-z
2. Drucker, D. J. (2018). The cardiovascular biology of glucagon-like peptide-1. *Cell Metabolism, 27*(4), 849-857. https://doi.org/10.1016/j.cmet.2018.03.001
3. Jorsal, A., Rørth, R., & Kistorp, C. (2017). Effect of liraglutide on left ventricular function in stable chronic heart failure

patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. *European Journal of Heart Failure, 19*(1), 69-77. https://doi.org/10.1002/ejhf.679
4. Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., & McMurray, J. J. (2020). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. *The Lancet Diabetes & Endocrinology, 8*(1), 10-22. https://doi.org/10.1016/S2213-8587(19)30417-3
5. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., & Shah, S. J. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine, 381*(21), 1995-2008. https://doi.org/10.1056/NEJMoa1911303
6. Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metabolism, 27*(4), 740-756. https://doi.org/10.1016/j.cmet.2018.03.001
7. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., ... & Yusuf, S. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *The Lancet, 394*(10193), 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
8. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine, 375*(4), 311-322. https://doi.org/10.1056/NEJMoa1603827
9. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., ... & van der Meer, P. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal, 37*(27), 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
10. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., & Husain, M. (2008). *Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor–dependent and –independent pathways. Circulation*, 117(18), 2340-2350. Preclinical study investigating the cardioprotective mechanisms of GLP-1 receptor activation in murine models. https://doi.org/10.1161/circulationaha.107.739938
11. Shiraki, A., Oyama, J. I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., ... & Node, K. (2012). The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis, 221(2), 375-382. https://doi.org/10.1016/j.atherosclerosis.2011.12.039
12. Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., ... & Shah, M. R. (2016). *Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA*, 316(5), 500-508. https://doi.org/10.1001/jama.2016.10260
13. Jorsal, A., Rørth, R., & Kistorp, C. (2017). *Effect of liraglutide on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. European Journal of Heart Failure*, 19(1), 69-77 https://doi.org/10.1002/ejhf.657
14. Fudim, M., White, J., Pagidipati, N. J., & Hernandez, A. F. (2019). *Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation*, 140(19), 1613-1622 https://doi.org/10.1161/circulationaha.119.041659
15. Neves, J. S., Packer, M., & Ferreira, J. P. (2023). *Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials. Journal of Cardiac Failure*, 29(2), 123-130. https://doi.org/10.1016/j.cardfail.2023.03.017
16. Sokos, G. G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G. J., Maher, T. D., ... & Kormos, R. L. (2006). *Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. The American Journal of Cardiology*, 97(5), 824-829 https://doi.org/10.1016/j.amjcard.2007.05.022
17. Read, P. A., Khan, F. Z., Heck, P. M., Hoole, S. P., & Dutka, D. P. (2010). DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circulation: Cardiovascular Imaging, 3(2), 195-201. https://doi.org/10.1161/circimaging.109.899377
18. Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., ... & Elmquist, J. K. (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. The Journal of clinical investigation, 110(1), 43-52. https://doi.org/10.1172/jci15595
19. Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A. M., Zhou, Y. Q., Riazi, A. M., ... & Husain, M. (2009). GLP-1 receptor agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 58(4), 975-983. https://doi.org/10.2337/db08-1193
20. Sokos, G. G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G. J., Maher, T. D., ... & Kormos, R. L. (2007). Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. The American Journal of Cardiology, 100(5), 824-829 https://doi.org/10.1016/j.amjcard.2007.05.022
21. Halbirk, M., Norrelund, H., Møller, N., Schmitz, O., Nielsen, R., Nielsen-Kudsk, J. E., ... & Wiggers, H. (2010). *Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American Journal of Physiology-Heart and Circulatory Physiology*, 298(3), H1096-H1102. https://doi.org/10.1152/ajpheart.00930.2009